10-K: Arrowhead Launches REDEMPLO, Expands Pipeline & Partnerships

Arrowhead Pharmaceuticals reports its first commercial launch of REDEMPLO for FCS, significant milestone payments from Sarepta and Novartis, and continued pipeline advancement in its latest 10-K filing.

Summary

• The U.S. Food and Drug Administration (FDA) approved REDEMPLO (plozasiran) as an adjunct to diet to reduce triglycerides in adults with Familial Chylomicronemia Syndrome (FCS) on November 18, 2025, marking the company's first commercial launch.
• Phase 3 studies (SHASTA-3, SHASTA-4, and SHASTA-5) for severe hypertriglyceridemia (sHTG) have been fully enrolled, with a supplemental New Drug Application (NDA) planned for 2026.
• A $200.0 million milestone payment was earned from Sarepta on November 20, 2025, for the second development milestone in a Phase 1/2 clinical study of ARO-DM1 (SRP-1003).
• A $100.0 million milestone payment from Sarepta was triggered on July 27, 2025, for ARO-DM1, settled with $53.2 million in common stock and $50.0 million in cash.
• A global licensing and collaboration agreement with Novartis for ARO-SNCA (Parkinson's Disease) and other CNS/cardiomyocyte targets was entered on August 29, 2025, and closed in October 2025, with an upfront payment of $200.0 million received.
• Regulatory clearance was filed to initiate Phase 1/2a clinical trials for ARO-DIMER-PA (mixed hyperlipidemia) and ARO-MAPT (Alzheimer's and tauopathies).
• A Phase 1/2a clinical trial of ARO-ALK7 for the treatment of obesity was initiated.
• Topline results from a Phase 1/2 clinical study of ARO-C3 showed reductions in alternative pathway complement activity and proteinuria.
• Interim results from a Phase 1/2a clinical study of ARO-CFB demonstrated dose-dependent reductions in circulating CFB protein by up to 90% and near-complete inhibition of alternative pathway hemolytic activity.
• Total revenue for the fiscal year ended September 30, 2025, increased significantly to $829.4 million, compared to $3.6 million in the prior year.
• Net loss attributable to Arrowhead Pharmaceuticals, Inc. substantially decreased to $1.6 million for the fiscal year ended September 30, 2025, from $599.5 million in the previous year.
• Cash, cash equivalents, and restricted cash increased to $226.5 million at September 30, 2025, from $102.7 million at September 30, 2024.
• Available-for-sale securities increased to $692.8 million at September 30, 2025, from $578.3 million at September 30, 2024.
• The company repurchased 2,660,989 shares of its common stock from Sarepta for $53.2 million in August 2025.
• The build-out of the manufacturing facility in Verona, Wisconsin, was substantially completed during the first quarter of fiscal 2025.

Sentiment

Score: 8

Explanation: The company achieved its first commercial product launch, significantly increased revenue, drastically reduced net losses, and secured substantial milestone payments and new collaboration agreements, indicating strong operational and financial progress and a favorable outlook.

Positives

• Achieved first commercial product launch with FDA approval of REDEMPLO (plozasiran) for Familial Chylomicronemia Syndrome (FCS) on November 18, 2025.
• Reported a substantial increase in total revenue to $829.4 million for fiscal year 2025, up from $3.6 million in 2024, primarily driven by collaboration agreements.
• Significantly reduced net loss attributable to Arrowhead Pharmaceuticals, Inc. to $1.6 million in fiscal year 2025, a major improvement from a $599.5 million net loss in 2024.
• Strengthened financial position with cash, cash equivalents, restricted cash, and available-for-sale securities totaling $919.4 million as of September 30, 2025.
• Secured significant milestone payments, including $100.0 million from Sarepta in July 2025 and $200.0 million from Sarepta in November 2025, and a $200.0 million upfront payment from Novartis in October 2025.
• Advanced the pipeline with new Phase 1/2a clinical trials initiated for ARO-DIMER-PA (mixed hyperlipidemia), ARO-MAPT (Alzheimer's and tauopathies), and ARO-ALK7 (obesity).
• Reported positive topline results from the Phase 1/2 clinical study of ARO-C3, showing reductions in alternative pathway complement activity and proteinuria.
• Presented positive interim results from the Phase 1/2a clinical study of ARO-CFB, demonstrating significant reductions in circulating CFB protein and alternative pathway activity.
• Completed enrollment for Phase 3 SHASTA-3, SHASTA-4, and MUIR-3 clinical trials for severe hypertriglyceridemia (sHTG), with a supplemental NDA filing anticipated in 2026.
• Expanded internal manufacturing capabilities with the substantial completion of a state-of-the-art GMP manufacturing facility in Verona, Wisconsin.

Negatives

• The company continues to incur net losses, albeit significantly reduced in fiscal 2025, and expects operating losses to continue for the foreseeable future.
• Substantial additional funds will be required to complete research and development activities and commercialization efforts.
• The terms of the Sixth Street Financing Agreement and existing indebtedness impose restrictive covenants and require significant payments, potentially limiting business flexibility.
• The company faces potential product liability exposure from REDEMPLO and any other approved product candidates.
• Uncertainty exists regarding the extent to which government authorities and health insurers will establish adequate reimbursement levels and pricing policies for approved products.
• The company is involved in patent infringement litigation with Ionis Pharmaceuticals, Inc. regarding plozasiran, which could result in substantial costs and liability.
• Reliance on single or limited third-party manufacturers for critical materials and commercial products poses supply chain risks.

Risks

• Future success is substantially dependent on the ability to timely complete clinical trials, obtain marketing approval, and successfully commercialize clinical-stage product candidates, including REDEMPLO.
• There are substantial risks inherent in attempting to commercialize new drugs, and the company may not be able to successfully develop additional products for commercial use.
• Clinical development is a lengthy and expensive process with uncertain outcomes and the potential for substantial delays, and there is no assurance that product candidates will obtain regulatory approval.
• Clinical trials may not yield successful results, or may reveal significant adverse events, toxicities, or other side effects that could impede regulatory approval or market acceptance.
• Results of earlier studies or clinical trials may not be predictive of future clinical trial results, and initial studies may not establish an adequate safety or efficacy profile.
• The company faces potential product liability exposure from the use of product candidates in clinical trials and the sale of REDEMPLO or any other approved products.
• The successful commercialization of REDEMPLO or any other approved product candidates will depend in part on adequate reimbursement levels and pricing policies from government authorities and health insurers.
• Commercialization, collaborative, and other arrangements may give rise to disputes over commercial terms, contract interpretation, and intellectual property ownership or protection.
• Fast Track or Breakthrough Therapy product designations may not lead to a faster development or regulatory review or approval process, nor do they increase the likelihood of marketing approval.
• Clinical trials for product candidates are conducted outside the United States, and the FDA and comparable foreign regulatory authorities may not accept data from such trials.
• Even with FDA approval in the United States, approval to commercialize product candidates outside the U.S. may never be obtained, limiting full market potential.
• Approval of generic versions of REDEMPLO or other products, or failure to grant appropriate periods of data or market exclusivity, could adversely affect sales.
• Failure to comply with regulatory requirements or unanticipated problems with products may result in various adverse actions, such as suspension or withdrawal of products or facility closure.
• Pharmaceutical and biological product marketing is subject to substantial regulation, and non-compliance can adversely affect the business.
• The ability to protect patents and other proprietary rights is uncertain, exposing the company to the possible loss of competitive advantage.
• The company is party to technology license agreements with third parties that require satisfaction of obligations to keep them effective, and termination could seriously and adversely affect technology and business.
• The company may be and has been subject to patent infringement claims, which could result in substantial costs and liability and prevent commercialization of potential products.
• The business model assumes revenue generation through marketing or out-licensing products, but product candidates are in various stages of development, providing limited information for business evaluation.
• Additional relationships with strategic and development partners may be needed to fully develop product candidates and market approved products.
• The ability to generate milestone and royalty payments under current and potential future licensing and collaboration agreements is substantially controlled by partners.
• A considerable amount of control over intellectual property may be lost, and anticipated revenues may not be received in strategic transactions, particularly when consideration is contingent on milestones.
• Commercial acceptance of REDEMPLO and other product candidates is necessary to generate revenues and achieve profitability.
• If market opportunities for REDEMPLO or any other approved product candidates are smaller than expected, financial condition and results of operations could be materially adversely affected.
• Limited internal manufacturing capability and reliance on third-party manufacturers for clinical supplies and commercial products could adversely affect development and commercialization.
• Reliance on third parties to conduct clinical trials means their failure to fulfill obligations may adversely affect product development.
• Difficulty may be experienced in expanding operations successfully as the pipeline evolves and moves toward commercializing drugs.
• Use of biological materials, hazardous materials, chemicals, and radioactive compounds requires compliance with environmental and health and human safety laws, non-compliance of which could adversely affect the business.
• Operations, including relationships with healthcare providers, physicians, and third-party payers, are subject to anti-kickback, fraud and abuse, and other healthcare laws and regulations, exposing the company to liability for violations.
• Actions of distributors and specialty pharmacies could affect the ability to sell or market products profitably, and fluctuations in their buying or distribution patterns could adversely affect revenues.
• The company has a history of net losses and expects to continue to incur them, and may not achieve or maintain profitability.
• Substantial additional funds will be required to complete research and development activities.
• The terms of the Sixth Street Financing Agreement and indebtedness could adversely affect operations and limit the ability to plan for or respond to business changes, with potential for accelerated repayment if restrictions are not complied with.
• Operating results may fluctuate significantly, making future operating results difficult to predict and potentially causing them to fall below expectations.
• The ability to utilize net operating loss carryforwards and other tax benefits may be limited.
• The company could be subject to additional tax liabilities.
• The business is subject to changing regulations for corporate governance and public disclosure, increasing costs and risk of noncompliance.
• The Board of Directors has the authority to issue shares of blank check preferred stock, which may make an acquisition of the company more difficult.
• The company does not intend to declare cash dividends on its common stock.
• If securities or industry analysts do not publish research reports or make adverse recommendations, the stock price and trading volume may decline.
• The market for purchases and sales of common stock may be limited, and the sale of a limited number of shares could cause the price to fall sharply.
• The common stock price has fluctuated significantly and may continue to do so, without regard to operating results and prospects.
• Stockholder equity interest may be substantially diluted in any additional equity issuances.
• The company is subject to stringent and evolving U.S. and foreign laws, regulations, rules, contractual obligations, policies, and other obligations related to data privacy and security.
• Unfavorable global economic conditions, health epidemics, military conflicts, geopolitical and trade disputes, or other factors may adversely affect business and financial results.
• Drug development is time-consuming, expensive, and risky.
• Evolving regulatory standards, including as a result of changes in government leadership, make it difficult to accurately predict the likelihood of marketing approval.

Future Outlook

The company plans to file a supplemental NDA for REDEMPLO in severe hypertriglyceridemia (sHTG) in 2026, pending successful completion of Phase 3 studies, and intends to progressively build its commercial capabilities for this higher prevalence disease. It expects to begin generating revenue from sales of REDEMPLO in the upcoming fiscal year. The company projects eligibility to receive up to $13.4 billion in additional developmental, regulatory, and sales milestones, plus various royalties from existing licensing and collaboration agreements. Liquidity is expected to be sufficient to fund operations for at least the next twelve months. The company anticipates spending an additional $0.1 million to complete the build-out of its Verona facilities and expects to make $40.0 million in prepayments on its Credit Facility within the next 12 months, in addition to a $66.7 million prepayment made in November 2025. The company does not expect a material impact from new accounting standards (ASU 2023-09) but acknowledges uncertainty regarding the impact of the Supreme Court's overruling of the Chevron doctrine and potential agency reorganizations at the FDA on regulatory review timelines and industry policies.

Management Comments

• "The Company develops medicines that treat intractable diseases by silencing the genes that cause them."
• "The Company recently achieved a transformational milestone with its first commercial launch in 2025, when the U.S. Food and Drug Administration ('FDA') approved REDEMPLO (plozasiran) as an adjunct to diet to reduce triglycerides in adults with Familial Chylomicronemia Syndrome ('FCS')."
• "The Company has built a commercial organization to support marketing in FCS, a rare disease, and plans to progressively build its commercial capabilities to also support marketing in sHTG, a higher prevalence disease which will require a larger commercial footprint."
• "The Company believes that for RNAi to reach its true potential, it must target organs outside the liver. The Company is leading this expansion with the TRiM platform, which has shown the potential to reach multiple tissues throughout the body."
• "Based upon the Company's current cash and investment resources and operating plan, the Company expects to have sufficient liquidity to fund its operations through at least the next twelve months from the date of the issuance of these consolidated financial statements."

Industry Context

The company operates in the rapidly evolving RNA interference (RNAi) therapeutics field, which aims to treat intractable diseases by silencing disease-causing genes. Its proprietary TRiM platform is designed to enable tissue-specific targeting beyond the liver, positioning it as a leader in expanding RNAi delivery capabilities. The company's strategy of forming multiple license and collaboration agreements with major pharmaceutical companies (Sarepta, Amgen, Takeda, GSK, Novartis, Sanofi) is a common industry practice to share development risks, expand technology reach, and secure non-dilutive capital. The industry faces significant challenges including lengthy and expensive drug development, stringent regulatory approval processes, intense competition from other biotech and pharmaceutical companies (including those leveraging AI for discovery), and increasing pressure on drug pricing and reimbursement from global healthcare systems and government initiatives like the Inflation Reduction Act. Evolving regulatory standards and geopolitical events also contribute to an unpredictable operating environment.

Comparison to Industry Standards

• The company's TRiM platform, designed to deliver siRNA to seven cell types beyond the liver, represents a leading-edge approach in the RNAi field, which traditionally focused on liver-targeted therapies.
• The first commercial launch of REDEMPLO for Familial Chylomicronemia Syndrome (FCS), a rare disease, aligns with a common industry trend of targeting orphan indications, which often benefit from specific regulatory incentives and market exclusivity.
• The development of ARO-DIMER-PA, a dual-functional RNAi molecule targeting two genes simultaneously, is highlighted as an important step forward for the RNAi field, showcasing innovation beyond single-target therapies common in the industry.
• The company's extensive network of collaborations with major pharmaceutical partners (Sarepta, Amgen, Takeda, GSK, Novartis, Sanofi) is a standard and effective strategy in the biotechnology industry for risk sharing, leveraging external expertise, and accessing broader markets.

Management Changes

Corporate Governance

Legal Proceedings

• On September 10, 2025, the Company filed a Complaint for Declaratory Judgment in the United States District Court for the District of Delaware against Ionis Pharmaceuticals, Inc., seeking to declare U.S. Patent No. 9,593,333 invalid and not infringed by the company's planned commercialization of investigational plozasiran.
• On September 11, 2025, Ionis Pharmaceuticals, Inc. filed a Complaint for Patent Infringement against the Company in the United States District Court for the Central District of California, alleging patent infringement of U.S. Patent No. 9,593,333 by the company's planned commercialization of investigational plozasiran and seeking damages.

Related Party Transactions

• In August 2025, the company repurchased 2,660,989 shares of its common stock from Sarepta for $53.2 million, as part of a $100.0 million milestone payment for ARO-DM1. Sarepta no longer holds an equity position in the company.
• Visirna Therapeutics, Inc. (Visirna) is a majority-owned subsidiary of the Company, and its financial statements are consolidated.
• Visirna Therapeutics HK Limited, a wholly-owned subsidiary of Visirna, entered into an Asset Purchase Agreement with Genzyme Corporation (Sanofi) for the rights to investigational plozasiran in Greater China.

Stakeholder Impact

• Shareholders: Potential for increased share value due to the first commercial product launch, significant revenue growth, reduced net losses, and substantial milestone payments from new and existing collaborations. However, risks of future equity dilution, stock price volatility, and ongoing litigation remain.
• Patients: New treatment option (REDEMPLO) for Familial Chylomicronemia Syndrome (FCS) is now available. Potential for future treatments for severe hypertriglyceridemia (sHTG), homozygous familial hypercholesterolemia (HoFH), metabolic-dysfunction associated steatohepatitis (MASH), obesity, Alzheimer's disease, Parkinson's disease, and complement-mediated diseases through pipeline advancement.
• Employees: Continued workforce expansion, competitive compensation packages, and a focus on inclusion and development initiatives. However, the pharmaceutical industry faces labor shortages and inflationary pressures on salaries.
• Partners (Sarepta, Novartis, Takeda, GSK, Amgen, Sanofi): Continued collaboration and potential for significant milestone and royalty payments based on successful development and commercialization of licensed products.
• Creditors (Sixth Street Lending Partners, Bank of Zhejiang): Debt obligations and restrictive covenants from financing agreements, requiring ongoing payments and adherence to financial thresholds.

Next Steps

• File a supplemental NDA for REDEMPLO in severe hypertriglyceridemia (sHTG) in 2026, pending successful completion of Phase 3 studies.
• Progressively build commercial capabilities to support marketing in sHTG, a higher prevalence disease.
• Continue to develop and advance its pipeline and partnered candidates.
• Complete the remaining build-out of the Verona facilities, with an expected additional expenditure of $0.1 million.
• Make $40.0 million of prepayments on the Credit Facility within the next 12 months, in addition to a $66.7 million prepayment made in November 2025.
• Negotiate and execute a pharmacovigilance agreement with Novartis prior to the first dosing of a patient in any Clinical Trial with a Licensed Product.
• Negotiate clinical or commercial supply agreements with Novartis if Novartis exercises its manufacturing options.
• Potentially receive up to $25.0 million in additional milestones from Novartis over the next 12 months.
• Potentially receive up to $250.0 million in additional milestones from Sarepta over the next 12 months.

Key Dates

Recommendation

The company has achieved a pivotal milestone with its first FDA-approved product and commercial launch, REDEMPLO, which is expected to generate product revenue in the upcoming fiscal year. This, combined with a substantial increase in overall revenue from strategic collaborations and a significant reduction in net losses, demonstrates strong operational execution and financial improvement. The robust pipeline, including multiple candidates in Phase 3 and new programs entering clinical trials, along with substantial potential future milestone payments from partnerships, indicates strong growth prospects. While risks exist, the positive developments outweigh them, suggesting a favorable outlook for investors.

Keywords

RNAi therapeutics, gene silencing, drug development, clinical trials, FDA approval, rare diseases, Familial Chylomicronemia Syndrome, severe hypertriglyceridemia, Parkinson's disease, Alzheimer's disease, obesity, MASH, AATD, chronic hepatitis B, complement-mediated disease, TRiM platform, biotechnology, pharmaceuticals, collaborations, intellectual property, regulatory affairs, manufacturing, plozasiran, ARO-DM1, ARO-SNCA